Plain-English translation of NCT06639724 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether a medication called fostamatinib, when combined with two standard chemotherapy drugs (gemcitabine and nab-paclitaxel), can improve outcomes for people with pancreatic cancer that can be surgically removed. The medication works by helping your immune system fight the cancer more effectively. You would take the medication by mouth twice daily, along with chemotherapy infusions, before surgery, then continue for a few cycles after surgery.
Pancreatic cancer is notoriously difficult to treat because tumors create an environment that suppresses the immune system's ability to attack cancer cells. Early research shows this medication may help reprogram immune cells to better recognize and fight the cancer, so this trial aims to see if this approach works in real patients.
You likely qualify if…
You likely don't qualify if…
You would receive 4 cycles of chemotherapy infusions (given intravenously on days 1, 8, and 15 of each 28-day cycle) combined with the new medication taken by mouth twice daily. After completing these 4 cycles, you would have surgery to remove the tumor, followed by 2 more cycles of chemotherapy and medication. The study team would follow you for up to 2 years after enrollment to monitor your health, check for side effects, and see how well the treatment works.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States